Alphatec (NASDAQ:ATEC) Major Shareholder Sells $4,688,719.20 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) major shareholder Squadron Capital Llc sold 221,166 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $21.20, for a total value of $4,688,719.20. Following the completion of the transaction, the insider directly owned 10,673,879 shares of the company’s stock, valued at approximately $226,286,234.80. The trade was a 2.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Tuesday, December 9th, Squadron Capital Llc sold 28,834 shares of Alphatec stock. The stock was sold at an average price of $21.03, for a total transaction of $606,379.02.
• On Monday, November 24th, Squadron Capital Llc sold 250,000 shares of Alphatec stock. The stock was sold at an average price of $20.62, for a total value of $5,155,000.00.
• On Wednesday, November 12th, Squadron Capital Llc sold 250,000 shares of Alphatec stock. The stock was sold at an average price of $20.80, for a total value of $5,200,000.00.

Alphatec Stock Up 0.3%

Shares of NASDAQ ATEC opened at $19.96 on Friday. Alphatec Holdings, Inc. has a 52-week low of $8.69 and a 52-week high of $22.66. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99. The company’s 50 day moving average price is $18.42 and its 200-day moving average price is $15.08. The company has a market capitalization of $2.97 billion, a P/E ratio of -19.19 and a beta of 1.08.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.09. The business had revenue of $196.50 million for the quarter, compared to the consensus estimate of $182.78 million. The firm’s revenue for the quarter was up 30.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.28) EPS. Equities analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Hedge Funds Weigh In On Alphatec

Hedge funds and other institutional investors have recently modified their holdings of the business. Nuveen LLC bought a new position in Alphatec in the 1st quarter valued at $135,874,000. Granite Investment Partners LLC raised its stake in shares of Alphatec by 320.6% during the 2nd quarter. Granite Investment Partners LLC now owns 1,720,944 shares of the medical technology company’s stock worth $19,102,000 after purchasing an additional 1,311,748 shares during the period. MetLife Investment Management LLC boosted its holdings in shares of Alphatec by 1,818.5% in the 1st quarter. MetLife Investment Management LLC now owns 1,213,943 shares of the medical technology company’s stock worth $12,309,000 after buying an additional 1,150,669 shares during the last quarter. Driehaus Capital Management LLC bought a new position in Alphatec during the first quarter valued at about $10,398,000. Finally, American Century Companies Inc. increased its holdings in Alphatec by 16.9% during the first quarter. American Century Companies Inc. now owns 5,830,031 shares of the medical technology company’s stock worth $59,117,000 after buying an additional 840,974 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. HC Wainwright boosted their target price on shares of Alphatec from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Lake Street Capital set a $25.00 price objective on Alphatec and gave the stock a “buy” rating in a report on Friday, October 31st. Wells Fargo & Company increased their price objective on Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday, October 16th. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 target price (up previously from $20.00) on shares of Alphatec in a research report on Friday, October 31st. Finally, Stifel Nicolaus started coverage on Alphatec in a report on Tuesday, October 28th. They set a “buy” rating and a $20.00 price target for the company. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.45.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.